Phase III Trial Enrollment Reached (75%) for Promising Anti-Inflammatory and Anti-Fibrotic Cardiac Therapies by Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)

$CRDL Target Recruitment Anticipated by End of Q2 2026, with Potential to Extend into Q3 to Accommodate Enrollment from Additional Clinical Sites Late-Stage Life Sciences…
posteditor
posteditor
Articles: 17424

Other News